{"id":"F2024L01151","name":"Food Standards (Proposal P1028 – Infant Formula – Consequential Amendments) Variation","slug":"food-standards-proposal-p1028-infant-formula-consequential-amendments-variation","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"in_force","isInForce":true,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":105361,"registerId":"commonwealth-F2024L01151-current","compilationNumber":null,"startDate":"2026-04-03","status":"InForce","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"2","sectionType":"section","heading":"Variation to standards in the Australia New Zealand Food Standards Code","content":"2 Variation to standards in the Australia New Zealand Food Standards Code\n\n(1) The Schedules to this instrument vary Standards in the Australia New Zealand Food Standards Code.\n\n(2) Each Standard that is specified in a Schedule to this instrument is amended as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.\n\n","sortOrder":0},{"sectionNumber":"3","sectionType":"section","heading":"Commencement","content":"3 Commencement\n\nThis instrument commences immediately after the commencement of the Food Standards (Proposal P1028 – Infant Formula) Variation.\n\n","sortOrder":1},{"sectionNumber":"4","sectionType":"section","heading":"Effect of the variations made by this instrument","content":"4 Effect of the variations made by this instrument\n\n(1) Section 1.1.1—9 of Standard 1.1.1 does not apply to the variations made by this instrument.\n\n(2) During the transition period, a food product may be sold if the product complies with one of the following:\n\n(a) the Code as in force without the variations made by the instruments; or\n\n(b) the Code as amended by the variations made by the instruments.\n\n(3) For the purposes of this clause:\n\n(a) the instruments means:\n\n(i) this instrument; and\n\n(ii) the Food Standards (Proposal P1028 – Infant Formula) Variation;\n\n(b) the transition period means the period commencing on the date of commencement of the Food Standards (Proposal P1028 – Infant Formula) Variation and ending 60 months after that date of commencement.\n\n","sortOrder":2},{"sectionNumber":"Sch 1","sectionType":"schedule","heading":null,"content":"Schedule 1\n\n","sortOrder":3},{"sectionNumber":"Sch 29","sectionType":"schedule","heading":"Special purpose foods","content":"Schedule 29—Special purpose foods\n\n\\[1\\] Sections S29—2 to S29—10\n\nRepeal the sections, substitute:\n\nS29—2 Infant formula products—calculation of energy content\n\n(1) For paragraph 2.9.1—4(2)(a), the energy content of infant formula product must be calculated using:\n\n(a) the energy contributions of the following \\*components only:\n\n(i) fat; and\n\n(ii) protein; and\n\n(iii) carbohydrate; and\n\n(b) the relevant energy factors set out in section S11—2.\n\n(2) The energy content of an infant formula product must be expressed in kilojoules.\n\nS29—2A Infant formula products—calculation of protein content\n\nFor paragraph 2.9.1—4(2)(b), the protein content of infant formula product must be calculated by multiplying the nitrogen content of the product by a nitrogen‑to‑protein conversion factor of 6.25.\n\nS29—2B Infant formula products—calculation of vitamin A content\n\nFor paragraph 2.9.1—4(2)(c), the vitamin A content of infant formula products must be calculated using only the retinol forms of vitamin A prescribed in Column 1 of Table S29—23.\n\nS29—3 Infant formula products—L-amino acids that must be present\n\nFor subsection 2.9.1—6(5) and section 2.9.1—33, the table is:\n\nL-amino acids that must be present in infant formula products\n\n| L-amino acid | Minimum amount per 100 kJ |\n| ------------- | ------------------------- |\n| Cysteine | 9 mg |\n| Histidine | 10 mg |\n| Isoleucine | 22 mg |\n| Leucine | 40 mg |\n| Lysine | 27 mg |\n| Methionine | 6 mg |\n| Phenylalanine | 19 mg |\n| Threonine | 18 mg |\n| Tryptophan | 8 mg |\n| Tyrosine | 18 mg |\n| Valine | 22 mg |\n\nS29—4 Infant formula products—limits on fatty acids\n\nFor paragraphs 2.9.1—7(1)(g) and 2.9.1—34(1)(g), the table is:\n\nLimits on fatty acids that may be present in infant formula products\n\n| Column 1 | Column 2 | |\n| ----------------------- | ----------------------------------------- | --- |\n| Substance | Maximum amountper 100 kJ | |\n| Docosahexaenoic acid | 12 mg | |\n| Total trans fatty acids | Not more than 4% of the total fatty acids | |\n| Erucic acid (22:1) | Not more than 1% of the total fatty acids | |\n\nS29—5 Vitamins, minerals, electrolytes and other substances required in infant formula and special medical purpose product for infants\n\nFor sections 2.9.1—7(2)(b)(i), 2.9.1—8(1), 2.9.1—34(2)(b) and 2.9.1­—36(1), the table is:\n\nVitamins, minerals, electrolytes and other nutritive substances required in infant formula and special medical purpose product for infants\n\n

Column 1

Column 2

Column 3

Column 4

Substance

Minimum amount
per 100 kJ

Maximum amount
per 100 kJ

Guidance upper level
per 100 kJ (see Note)

Vitamins

Vitamin A

14 μg RE

43 μg RE

Vitamin D

0.24 μg

0.63 μg

Vitamin C

1.7 mg

17 mg

Thiamin

10 μg

72 µg

Riboflavin

14.3 μg

120 µg

Niacin

72 μg

359 µg

Vitamin B6

8 μg

42 µg

Folic acid

2.4 μg

12 µg

Pantothenic acid

96 μg

478 µg

Vitamin B12

0.02 μg

0.36 µg

Biotin

0.24 μg

2.4 µg

Vitamin E

0.14 mg α-TE

1.2 mg α-TE

Vitamin K

0.24 μg

6 µg

Minerals

Calcium

12 mg

35 mg

Phosphorus

6 mg

24 mg

Magnesium

1.2 mg

3.6 mg

Iron

0.14 mg

0.48 mg

Iodine

2.4 μg

14 µg

Copper

8 μg

29 µg

Zinc

0.12 mg

0.36 mg

Manganese

0.24 μg

24 μg

Selenium

0.48 μg

2.2 µg

Electrolytes

Chloride

12 mg

38 mg

Sodium

4.8 mg

14 mg

Potassium

14 mg

43 mg

Other essential substances

Choline

1.7 mg

12 mg

L-carnitine

0.3 mg

0.8 mg

Inositol

1 mg

10 mg

\n```\n\nNote It is recommended that infant formula and a special medical purpose product for infants contain a substance listed in Column 1 of the table in an amount that is not more than the amount (if any) specified for that substance in Column 4 of the table. The amounts specified in Column 4 are Guidance Upper Levels and are recommended upper levels for nutrients which pose no significant risks on the basis of current scientific knowledge. These levels are values derived on the basis of meeting nutritional requirements of infants and an established history of apparent safe use. These Guidance Upper Levels should not be exceeded unless higher nutrient levels cannot be avoided due to high or variable contents in constituents of infant formulas or special medical purpose product for infants; or due to technological reasons.\n\nS29—6 Vitamins, minerals and electrolytes required in follow-on formula\n\nFor subparagraph 2.9.1—7(2)(b)(ii) and subsection 2.9.1—8(2), the table is:\n\nVitamins, minerals and electrolytes required in follow-on formula\n\n| Column 1 | Column 2 | Column 3 | Column 4 |\n| ------------------------------- | ------------------------ | ------------------------ | ----------------------------------------- |\n| Vitamin, mineral or electrolyte | Minimum amountper 100 kJ | Maximum amountper 100 kJ | Guidance upper levelper 100 kJ (see Note) |\n| Vitamins | | | |\n| Vitamin A | 14 μg RE | 43 μg RE | |\n| Vitamin D | 0.24 μg | 0.72 μg | |\n| Vitamin C | 1.7 mg | | 17 mg |\n| Thiamin | 10 μg | | 72 µg |\n| Riboflavin | 14.3 μg | | 120 µg |\n| Niacin | 72 μg | | 359 µg |\n| Vitamin B6 | 8 μg | | 42 µg |\n| Folic acid | 2.4 μg | | 12 µg |\n| Pantothenic acid | 96 μg | | 478 µg |\n| Vitamin B12 | 0.02 μg | | 0.36 µg |\n| Biotin | 0.24 μg | | 2.4 µg |\n| Vitamin E | 0.14 mg α-TE | | 1.2 mg α-TE |\n| Vitamin K | 0.24 μg | | 6 µg |\n| Minerals | | | |\n| Calcium | 12 mg | | 43 mg |\n| Phosphorus | 6 mg | | 24 mg |\n| Magnesium | 1.2 mg | | 3.6 mg |\n| Iron | 0.24 mg | 0.48 mg | |\n| Iodine | 2.4 μg | | 14 µg |\n| Copper | 8 μg | | 29 µg |\n| Zinc | 0.12 mg | | 0.36 mg |\n| Manganese | 0.24 μg | | 24 μg |\n| Selenium | 0.48 μg | | 2.2 µg |\n| Electrolytes | | | |\n| Chloride | 12 mg | 38 mg | |\n| Sodium | 4.8 mg | 14 mg | |\n| Potassium | 14 mg | 43 mg | |\n\nNote It is recommended that follow-on formula contain a substance listed in Column 1 of the table in an amount that is not more than the amount (if any) specified for that substance in column 4 of the table. The amounts specified are Guidance Upper Levels and are recommended upper levels for nutrients which pose no significant risks on the basis of current scientific knowledge. These levels are values derived on the basis of meeting nutritional requirements of infants and an established history of apparent safe use. The Guidance Upper Levels should not be exceeded unless higher nutrient levels cannot be avoided due to high or variable contents in constituents of follow-on formula or due to technological reasons.\n\nS29—7 Optional nutritive substances in infant formula and special medical purpose product for infants\n\nFor subsection 2.9.1—9(1) and section 2.9.1—37, the table is set out below.\n\nOptional nutritive substances in infant formula and special medical purpose product for infants\n\n| Column 1 | Column 2 | Column 3 |\n| --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------- | --------------------------------------------------------------- |\n| Substance | Minimum amount per 100 kJ | Maximum amount per 100 kJ |\n| 2′-fucosyllactose permitted for use by Standard 1.5.23′-sialyllactose sodium salt permitted for use by Standard 1.5.26′-sialyllactose sodium salt permitted for use by Standard 1.5.2A combination of 2′-fucosyllactose and difucosyllactose, permitted for use by Standard 1.5.2 | | 96 mg8 mg16 mg96 mg |\n| A combination of: 2′-fucosyllactose permitted for use by Standard 1.5.2; and lacto-N-neotetraose permitted for use by Standard 1.5.2 | | 96 mg which contains not more than 24 mg of lacto-N-neotetraose |\n| Adenosine-5′-monophosphate | | 0.36 mg |\n| Cytidine-5′-monophosphate | | 0.6 mg |\n| Guanosine-5′monophosphate | | 0.4 mg |\n| Inosine-5′-monophosphate | | 0.24 mg |\n| Lactoferrinlacto-N-tetraose permitted for use by Standard 1.5.2 | | 40 mg32 mg |\n| Lutein | 1.5 µg | 5 µg |\n| Taurine | | 2.9 mg |\n| Uridine-5′-monophosphate | | 0.42 mg |\n\nS29—8 Optional nutritive substances in follow-on formula\n\nFor subsection 2.9.1—9(2), the table is set out below.\n\nOptional nutritive substances in follow-on formula\n\n| Column 1 | Column 2 | Column 3 | Column 4 |\n| --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------- | --------------------------------------------------------------- | ------------------------------------------ |\n| Substance | Minimum amount per 100 kJ | Maximum amount per 100 kJ | Guidance upper level per 100 kJ (see Note) |\n| 2′-fucosyllactose permitted for use by Standard 1.5.23′-sialyllactose sodium salt permitted for use by Standard 1.5.26′-sialyllactose sodium salt permitted for use by Standard 1.5.2A combination of 2′-fucosyllactose and difucosyllactose, permitted for use by Standard 1.5.2 | | 96 mg8 mg16 mg96 mg | |\n| A combination of: 2′-fucosyllactose permitted for use by Standard 1.5.2; and lacto-N-neotetraose permitted for use by Standard 1.5.2 | | 96 mg which contains not more than 24 mg of lacto-N-neotetraose | |\n| Adenosine-5′-monophosphate | | 0.36 mg | |\n| L-carnitine | 0.3 mg | | |\n| Choline | | | 12 mg |\n| Cytidine-5′-monophosphate | | 0.6 mg | |\n| Guanosine-5′-monophosphate | | 0.4 mg | |\n| Inosine-5′-monophosphate | | 0.24 mg | |\n| Lactoferrinlacto-N-tetraose permitted for use by Standard 1.5.2 | | 40 mg32 mg | |\n| Lutein | 1.5 µg | 5 µg | |\n| Inositol | | | 10 mg |\n| Taurine | | 2.9 mg | |\n| Uridine-5′-monophosphate | | 0.42 mg | |\n\nNote It is recommended that follow-on formula contain a substance listed in Column 1 of the table in an amount that is not more than the amount (if any) specified for that substance in Column 4 of the table. The amounts specified in Column 4 are Guidance Upper Levels and are recommended upper levels for nutrients which pose no significant risks on the basis of current scientific knowledge. These levels are values derived on the basis of meeting nutritional requirements of infants and an established history of apparent safe use. The Guidance Upper Levels should not be exceeded unless higher nutrient levels cannot be avoided due to high or variable contents in constituents of follow-on formula or due to technological reasons.\n\nS29—9 Permitted forms of nutritive substances in infant formula products\n\nFor paragraphs 2.9.1—10(b) and 2.9.1—38(b), the table is set out below.\n\nPermitted forms for nutritive substances used in infant formula products\n\n| Substance | Permitted forms |\n| --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------- |\n| 2′-fucosyllactose permitted for use by Standard 1.5.23′-sialyllactose sodium salt permitted for use by Standard 1.5.26'-sialyllactose sodium salt permitted for use by Standard 1.5.2A combination of 2′-fucosyllactose and difucosyllactose, permitted for use by Standard 1.5.2 | 2′-fucosyllactose3′-sialyllactose sodium salt6'-sialyllactose sodium salt2'-fucosyllactose and difucosyllactose |\n| A combination of: 2′-fucosyllactose permitted for use by Standard 1.5.2; and lacto-N-neotetraose permitted for use by Standard 1.5.2 | 2′-fucosyllactose and lacto-N-neotetraose |\n| Adenosine-5′-monophosphate | Adenosine-5′- monophosphate |\n| L-carnitine | L-carnitineL-carnitine hydrochlorideL-carnitine tartrate |\n| Choline | Choline chloride |\n| | Choline bitartrateCholineCholine citrateCholine hydrogen tartrate |\n| Cytidine-5′-monophosphate | Cytidine-5′-monophosphate |\n| Guanosine-5′-monophosphate | Guanosine-5′-monophosphate |\n| | Guanosine-5′-monophosphate sodium salt |\n| Inosine-5′-monophosphate | Inosine-5′-monophosphate |\n| | Inosine-5′-monophosphate sodium salt |\n| Lactoferrinlacto-N-tetraose permitted for use by Standard 1.5.2 | Bovine lactoferrinlacto-N-tetraose |\n| Lutein | Lutein from Tagetes erecta L. |\n| Inositol | Myo-inositol |\n| Taurine | Taurine |\n| Uridine-5′-monophosphate | Uridine-5′-monophosphate sodium salt |\n\nNote Section S29—23 lists the permitted forms of vitamins, minerals and electrolytes in infant formula products.\n\nS29—9A Infant formula products—conditions on use of permitted nutritive substances\n\nThe table for this section is as follows:\n\nConditions of use for permitted nutritive substances\n\n| Column 1 | Column 2 | Column 3 |\n| ----------- | ------------------ | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| Substance | Permitted Form | Conditions of use |\n| Lactoferrin | Bovine lactoferrin | During the exclusive use period, may only be sold under the brand Synlait for *use as a nutritive substance in an infant formula product.For the purposes of condition 1 above, exclusive use period means the period commencing on the date of gazettal of the Food Standards (Application A1253 – Bovine Lactoferrin in Infant Formula Products) Variation and ending 15 months after that date. |\n\nS29—10 Required format for a nutrition information statement\n\nThe table to this section is:\n\n

NUTRITION INFORMATION

Average quantity per 100 mL prepared formula

Energy

kJ

Protein

g

— Whey*

g

— Casein*

g

Fat

g

— Long chain polyunsaturated

fatty acids*

— Docosahexaenoic acid (DHA)*

mg

— Eicosapentaenoic acid (EPA)*

mg

— Arachidonic acid (ARA)*

mg

Carbohydrate

g

Vitamins

Vitamin A

μg

Vitamin B6

μg

Vitamin B12

μg

Vitamin C

mg

Vitamin D

μg

Vitamin E

mg

Vitamin K

μg

Biotin

μg

Niacin (B3)

μg

Folate

μg

Pantothenic acid (B5)

μg

Riboflavin (B2)

μg

Thiamin (B1)

μg

Minerals

Calcium

mg

Copper

μg

Iodine

μg

Iron

mg

Magnesium

mg

Manganese

μg

Phosphorus

mg

Selenium

μg

Zinc

mg

Chloride

mg

Potassium

mg

Sodium

mg

Other nutrients*

Choline*

mg

Inositol*

mg

L-carnitine*

mg

Additional

(insert any other substance used as a nutritive substance; or inulin-type fructans and / or galacto-oligosaccharides, to be declared)

g, mg, μg

\n```\n\nNote: \\*See the following.\n\nEntries and amounts for the following need only be included when stated in accordance with subsection 2.9.1—24(4), 2.9.1—24(5) and paragraph 2.9.1—25(6)(d): whey; casein; docosahexaenoic acid; eicosapentaenoic acid; arachidonic acid.\n\nThe heading ‘Other nutrients’ need only be included when required by subparagraph 2.9.1—25(2)(d)(ii) and paragraph 2.9.1—25(4)(a).\n\nThe heading ‘Long chain polyunsaturated fatty acids’ need only be included when required by paragraph 2.9.1—25(6)(a).\n\nEntries and amounts for choline, inositol, L-carnitine are included under the heading ‘Other nutrients’ when required by paragraph 2.9.1—25(4)(a) and under the heading ‘Additional’ when required by paragraph 2.9.1—25(4)(b).\n\nS29—10A Example of a nutrition information statement including quantities expressed as sold\n\nFor subsection 2.9.1—25(7), an example nutrition information statement including information expressed in accordance with subsection 2.9.1—24(7) is:\n\n

NUTRITION INFORMATION

Average quantity per 100 mL prepared formula

Quantity per 100 g powder (or 100 mL liquid concentrate)

Energy

kJ

kJ

Protein

g

g

— Whey

g

g

— Casein

g

g

Fat

g

g

— Long chain polyunsaturated

fatty acids

— Docosahexaenoic acid (DHA)

mg

mg

— Eicosapentaenoic acid (EPA)

mg

mg

— Arachidonic acid (ARA)

mg

mg

Carbohydrate

g

g

Vitamins

Vitamin A

μg

μg

Vitamin B6

μg

μg

Vitamin B12

μg

μg

Vitamin C

mg

mg

Vitamin D

μg

μg

Vitamin E

mg

mg

Vitamin K

μg

μg

Biotin

μg

μg

Niacin (B3)

μg

μg

Folate

μg

μg

Pantothenic acid (B5)

μg

μg

Riboflavin (B2)

μg

μg

Thiamin (B1)

μg

μg

Minerals

Calcium

mg

mg

Copper

μg

μg

Iodine

μg

μg

Iron

mg

mg

Magnesium

mg

mg

Manganese

μg

μg

Phosphorus

mg

mg

Selenium

μg

μg

Zinc

mg

mg

Chloride

mg

mg

Potassium

mg

mg

Sodium

mg

mg

Other nutrients

Choline

mg

mg

Inositol

mg

mg

L-carnitine

mg

mg

Additional

(insert any other substance used as a nutritive substance; or inulin-type fructans and / or galacto-oligosaccharides, to be declared)

g, mg, μg

g, mg, μg

\n```\n\n\\[2\\] After section S29—22\n\nS29—23 Permitted forms of vitamins, minerals and electrolytes in infant formula products, food for infants, formulated meal replacements (vitamin K) and food for special medical purposes\n\nFor sections 2.9.1—10(a), 2.9.1—38(a), 2.9.2—4, 2.9.2—5, 2.9.2—6, 2.9.3—3(2)(c)(iii) and 2.9.5—6, the table is:\n\nPermitted forms of vitamins, minerals and electrolytes in infant formula products, food for infants, formulated meal replacements (vitamin K) and food for special medical purposes\n\n| Vitamin, mineral or electrolyte | Permitted forms |\n| ------------------------------- | ----------------------------------------------------------------------------------------- |\n| Vitamin A | |\n| Retinol forms | vitamin A (retinol) |\n| | vitamin A acetate (retinyl acetate) |\n| | vitamin A palmitate (retinyl palmitate) |\n| | retinyl propionate |\n| Provitamin A forms | beta-carotene |\n| Vitamin C | L-ascorbic acid |\n| | L-ascorbyl palmitate |\n| | calcium ascorbate |\n| | potassium ascorbate |\n| | sodium ascorbate |\n| Vitamin D | vitamin D2 (ergocalciferol) |\n| | vitamin D3 (cholecalciferol) |\n| | vitamin D (cholecalciferol-cholesterol) |\n| Thiamin | thiamin hydrochloride |\n| | thiamin mononitrate |\n| Riboflavin | riboflavin |\n| | riboflavin-5′-phosphate, sodium |\n| Niacin | niacinamide (nicotinamide) |\n| Vitamin B6 | pyridoxine hydrochloride |\n| | pyridoxine-5′-phosphate |\n| Folate | Folic acid |\n| Pantothenic acid | calcium pantothenate |\n| | dexpanthenol |\n| | D-panthenol |\n| | calcium D-pantothenate |\n| | sodium D-pantothenate |\n| Vitamin B12 | cyanocobalamin |\n| | hydroxocobalamin |\n| Biotin | d-biotin |\n| Vitamin E | dl-α-tocopherol |\n| | d-α-tocopherol concentrate |\n| | tocopherols concentrate, mixed |\n| | d-α-tocopheryl acetate |\n| | dl-α-tocopheryl acetate |\n| | d-α-tocopheryl acid succinate |\n| | dl-α-tocopheryl succinate |\n| Vitamin K | Vitamin K1 as phylloquinone (phytonadione) |\n| Calcium | calcium carbonate |\n| | calcium chloride |\n| | calcium citrate |\n| | calcium gluconate |\n| | calcium glycerophosphate |\n| | calcium hydroxide |\n| | calcium lactate |\n| | calcium oxide |\n| | calcium phosphate, dibasic |\n| | calcium phosphate, monobasic |\n| | calcium phosphate, tribasic |\n| | calcium sulphate |\n| Chloride | calcium chloride |\n| | magnesium chloride |\n| | potassium chloride |\n| | sodium chloride |\n| Chromium | chromium sulphate |\n| Copper | copper gluconate |\n| | cupric sulphate |\n| | cupric citratecupric carbonate |\n| Iodine | potassium iodate |\n| | potassium iodide |\n| | sodium iodide |\n| Iron | ferric ammonium citrateferric citrate |\n| | ferric pyrophosphateferrous bisglycinate |\n| | ferrous citrate |\n| | ferrous fumarate |\n| | ferrous gluconate |\n| | ferrous lactate |\n| | ferrous succinate |\n| | ferrous sulphate |\n| Magnesium | magnesium carbonate |\n| | magnesium chloride |\n| | magnesium gluconate |\n| | magnesium oxide |\n| | magnesium phosphate, dibasic |\n| | magnesium phosphate, tribasic |\n| | magnesium sulphate |\n| | magnesium hydroxide carbonate |\n| | magnesium hydroxide |\n| | magnesium salts of citric acid |\n| Manganese | manganese carbonatemanganese chloridemanganese citrate |\n| | manganese gluconate |\n| | manganese sulphate |\n| Molybdenum | sodium molybdate VI |\n| Phosphorus | calcium glycerophosphate |\n| | calcium phosphate, dibasic |\n| | calcium phosphate, monobasic |\n| | calcium phosphate, tribasic |\n| | magnesium phosphate, dibasic |\n| | potassium phosphate, dibasic |\n| | potassium phosphate, monobasic |\n| | potassium phosphate, tribasic |\n| | sodium phosphate, dibasic |\n| | sodium phosphate, monobasic |\n| | sodium phosphate, tribasic |\n| Potassium | potassium bicarbonate |\n| | potassium carbonate |\n| | potassium chloride |\n| | potassium citrate |\n| | potassium glycerophosphate |\n| | potassium gluconate |\n| | potassium hydroxide |\n| | potassium phosphate, dibasic |\n| | potassium phosphate, monobasic |\n| | potassium phosphate, tribasicpotassium L-lactate |\n| Selenium | seleno methionine |\n| | sodium selenate |\n| | sodium selenite |\n| Sodium | sodium bicarbonate |\n| | sodium carbonate |\n| | sodium chloride |\n| | sodium chloride iodised |\n| | sodium citrate |\n| | sodium gluconate |\n| | sodium hydroxide |\n| | sodium iodide |\n| | sodium lactate |\n| | sodium phosphate, dibasic |\n| | sodium phosphate, monobasic |\n| | sodium phosphate, tribasic |\n| | sodium sulphate |\n| | sodium tartrate |\n| Zinc | zinc acetatezinc chloridezinc citrate (zinc citrate dihydrate or zinc citrate trihydrate) |\n| | zinc gluconatezinc lactate |\n| | zinc oxide |\n| | zinc sulphate |\n\n \n\n","sortOrder":4},{"sectionNumber":"Sch 2","sectionType":"schedule","heading":null,"content":"Schedule 2\n\nStandard 1.1.2—Definitions used throughout the Code\n\n\\[1\\] Subsection 1.1.2—2(3)\n\ninner package, in relation to a special medical purpose product for infants, means an individual package of the food that is:\n\n(a) contained and sold within another package that is labelled in accordance with Division 4 of Standard 2.9.1; and\n\n(b) not designed for individual sale, other than a sale by a \\*responsible institution to a patient or resident of the responsible institution.\n\nExample An example of an inner package is an individual sachet (or sachets) of a powdered food contained within a box that is fully labelled, being a box available for retail sale.\n\n\\[2\\] Subsection 1.1.2—2(3) (definition of medium chain triglycerides)\n\n\\[2A\\] Subsection 1.1.2—2(3) (definition of protein substitute)\n\n\\[3\\] Subsection 1.1.2—2(3) (paragraph (c) of the definition of warning statement)\n\nRepeal the paragraph, substitute:\n\n(c) subsection 2.9.1—21(1) (warning statements for infant formula product);\n\n\\[4\\] Subsection 1.1.2—3(2) (definitions—particular foods)\n\nspecial medical purpose product for infants means an infant formula product that is:\n\n1. represented as being:\n\n1. specially formulated for the dietary management of infants who have medically determined nutrient requirements (such as limited or impaired capacity to take, digest, absorb, metabolise or excrete ordinary food or certain nutrients in ordinary food); and\n\n1. suitable to constitute either the sole or principal liquid source of nourishment where dietary management cannot medically be achieved without use of the product; and\n\n(iii) for the dietary management of a medically diagnosed disease, disorder or condition of an infant; and\n\n1. intended to be used under medical supervision; and\n2. not suitable for general use.\n\n\\[5\\] Subsection 1.1.2—3(2) (definition of follow-on formula)\n\nfollow-on formula means an infant formula product that is represented as:\n\n(a) either a breast milk substitute or replacement for infant formula; and\n\n(b) being suitable to constitute the principal liquid source of nourishment in a progressively diversified diet for infants from the age of 6 months.\n\n\\[6\\] Subsection 1.1.2—3(2) (definition of infant formula)\n\ninfant formula means an infant formula product that is represented as:\n\n(a) a breast milk substitute for infants; and\n\n(b) satisfying by itself the nutritional requirements of infants under the age of 6 months.\n\n\\[7\\] Subsection 1.1.2—3(2) (definition of infant formula product)\n\ninfant formula product means a product based on milk or other edible food constituents of animal or plant origin which is represented as nutritionally adequate to serve by itself either as the sole or principal liquid source of nourishment for infants, depending on the age of the infant.\n\n\\[8\\] Subsection 1.1.2—3(2) (definition of pre-term formula)\n\n\\[8A\\] Subsection 1.1.2—8(2) (definition of novel food)\n\nRepeal the subsection, substitute:\n\n(2) Any of the following:\n\n(a) the presence of a food in a food for special medical purposes;\n\n(b) the presence of a food in a special medical purpose product for infants;\n\n(c) the use of a food as a food for special medical purpose;\n\n(d) the use of a food as a special medical purpose product for infants;\n\ndoes not constitute a history of human consumption in Australia or New Zealand in relation to that food for the purposes of this section\n\nStandard 1.2.3—Information requirements – warning statements, advisory statements and declarations\n\n\\[9\\] Paragraph 1.2.3—6(4)(b)\n\nRepeal the paragraph, substitute\n\n(b) a special medical purpose product for infants.\n\n\\[10\\] Note 2 to subsection 1.2.3—6(4)\n\nRepeal the note, substitute:\n\nNote 2 Division 4 of Standard 2.9.1 applies to a special medical purpose product for infants and sets out compositional and labelling requirements for such food.\n\nStandard 1.3.1—Food Additives\n\n\\[11\\] Subsection 1.3.1—3(2)\n\nAfter ‘any food’, insert ‘(other than an infant formula product)’\n\n\\[12\\] Paragraph 1.3.1—4(6)(k)\n\nRepeal the paragraph, substitute:\n\n(k) rosemary extract is calculated as the sum of carnosic acid and carnosol;\n\n(l) phosphoric acid and phosphates are calculated as phosphorus.\n\nStandard 1.5.1—Novel Foods\n\n\\[13\\] Note to subsection 1.5.1—2(2) (Definition of novel food)\n\nRepeal subsection (2) of the definition, substitute:\n\n(2) Any of the following:\n\n(a) the presence of a food in a food for special medical purposes;\n\n(b) the presence of a food in a special medical purpose product for infants;\n\n(c) the use of a food as a food for special medical purpose;\n\n(d) the use of a food as a special medical purpose product for infants;\n\ndo not constitute a history of human consumption in Australia or New Zealand in relation to that food for the purposes of this section.\n\n\\[13A\\] Section 1.5.1—3\n\nRepeal the section, substitute:\n\n1.5.1—3 Sale of novel foods\n\n(1) Despite paragraphs 1.1.1—10(5)(b) and (6)(f), a food offered for retail sale (other than an infant formula product) may consist of, or have as an ingredient, a \\*novel food if:\n\n(a) the novel food is listed in the table to section S25—2; and\n\n(b) any conditions of use specified in the corresponding row of that table are complied with.\n\nNote Novel foods are added to the table to section S25—2 by variations to the Code. When added for the first time, the conditions may include some that apply to the novel food only during the first 15 months after gazettal of the variation. Conditions may also deal with matters such as the following:\n\n· the need for preparation or cooking instructions, warning statements or other advice;\n\n· the need to meet specific requirements of composition or purity;\n\n· the class of food within which the food must be sold;\n\n· during the first 15 months after gazettal, the brand under which the food may be sold.\n\n(2) Despite paragraphs 1.1.1—10(5)(b) and (6)(f), an infant formula product for retail sale may consist of, or have as an ingredient or a \\*component, a novel food only if:\n\n(a) the novel food is listed in the table to section S25—2; and\n\n(b) the presence of that novel food in the infant formula product is expressly permitted by that table; and\n\n(c) any conditions of use specified in the corresponding row of that table are complied with.\n\nStandard 2.9.2—Food for infants\n\n\\[14\\] Section 2.9.2—4\n\nOmit ‘section S29—7’ (wherever occurring), substitute ‘section S29—23’.\n\n\\[15\\] Section 2.9.2—5\n\nOmit ‘section S29—7’ (wherever occurring), substitute ‘section S29—23’.\n\n\\[16\\] Subsection 2.9.2—6(3)\n\nStandard 2.9.3—Formulated meal replacements and formulated supplementary foods\n\n\\[17\\] Subparagraph 2.9.3—3(2)(c)(iii)\n\nStandard 2.9.5—Food for special medical purposes\n\n\\[18\\] Paragraph 2.9.5—6(1)(b)\n\n","sortOrder":5},{"sectionNumber":"Sch 8","sectionType":"schedule","heading":"Food additive names and code numbers (for statement of ingredients)","content":"Schedule 8—Food additive names and code numbers (for statement of ingredients)\n\n\\[19\\] The table to section S8—2 (food additive names—alphabetical listing)\n\n| dl-Alpha-tocopherol | 307c |\n| ------------------- | ---- |\n| Potassium hydroxide | 525 |\n| Sodium hydroxide | 524 |\n\n\\[20\\] The table to section S8—2 (food additive names—numerical listing)\n\nInsert in numerical order:\n\n| 307c | dl-Alpha-tocopherol |\n| ---- | ------------------- |\n| 524 | Sodium hydroxide |\n| 525 | Potassium hydroxide |\n\n","sortOrder":6},{"sectionNumber":"Sch 15","sectionType":"schedule","heading":"Substances that may be used as food additives","content":"Schedule 15—Substances that may be used as food additives\n\n\\[21\\] The table to section S15—5 (food classes 13.1, 13.1.1, 13.1.2 and 13.1.3)\n\nRepeal the food classes, substitute:\n\n

0B13.1 Infant formula products

270

Lactic acid

GMP

300

Ascorbic acid

50 mg/L

See Note 1, below.

301

Sodium ascorbate

50 mg/L

75 mg/L

See Note 1, below.

May only be added to polyunsaturated fatty acid preparations

302

Calcium ascorbate

50 mg/L

See Note 1, below.

304

Ascorbyl palmitate

50 mg/L

See Note 1, below.

304

Ascorbyl palmitate

10 mg/L

307b

Tocopherols concentrate, mixed

10 mg/L

307b

Tocopherols concentrate, mixed

30 mg/L

See Note 1, below

307c

dl-Alpha-tocopherol

10 mg/L

307c

dl-Alpha-tocopherol

30 mg/L

See Note 1, below

308

Gamma-tocopherol

10 mg/L

309

Delta-tocopherol

10 mg/L

322

Lecithin

5 000 mg/L

330

Citric acid

GMP

331

Sodium citrates

GMP

332

Potassium citrates

GMP

333

Calcium citrates

0.1 mg/L

As calcium, may only be added as part of a nutrient preparation

338

Phosphoric acid

450 mg/L

339

Sodium phosphates

450 mg/L

340

Potassium phosphates

450 mg/L

407

Carrageenan

300 mg/L

Only in a liquid product

410

Locust bean (carob bean) gum

1 000 mg/L

412

Guar gum

1 000 mg/L

Only in a liquid product that contains hydrolysed protein

414

Gum arabic (acacia)

10 mg/L

May only be added as part of a nutrient preparation

440

Pectins

10 000 mg/L

See Note 1, below

471

Mono- and diglycerides of fatty acids

4 000 mg/L

472c

Citric and fatty acid esters of glycerol

7 500 mg/L

Only in a powdered product

9 000 mg/L

Only in a liquid product

500

Sodium carbonates

2 000 mg/L

501

Potassium carbonates

2 000 mg/L

524

Sodium hydroxide

2 000 mg/L

525

Potassium hydroxide

2 000 mg/L

526

Calcium hydroxide

2 000 mg/L

551

Silicon dioxide (amorphous)

10 mg/L

May only be added as part of a nutrient preparation

1412

Distarch phosphate

5 000 mg/L

See Note 2, below.

1413

Phosphated distarch phosphate

5 000 mg/L

See Note 3, below.

1414

Acetylated distarch phosphate

5 000 mg/L

See Note 4, below.

1422

Acetylated distarch adipate

5 000 mg/L

See Note 5, below.

1440

Hydroxypropyl starch

5 000 mg/L

See Note 6, below.

1450

Starch sodium octenylsuccinate

100 mg/L

May only be added as part of a nutrient preparation

1 000 mg/L

May only be added to polyunsaturated fatty acid preparations

Note 1. For additives 300, 301, 302, 304, 307b, 307c, 440—the additive may only be used in follow-on formula products.

Note 2. Additive 1412 may only be used in:

  1. soy based infant formula product (other than follow-on formula) either singly or in combination with one or more of additives 1413, 1414 and 1440; and
  2. soy based follow-on formula either singly or in combination with one or more of additives 1413, 1414 and 1422.

Note 3. Additive 1413 may only be used in:

  1. soy based infant formula product (other than follow-on formula) either singly or in combination with one or more of additives 1412, 1414 and 1440; and
  2. soy based follow-on formula either singly or in combination with one or more of additives 1412, 1414 and 1422.

Note 4. Additive 1414 may only be used in:

  1. soy based infant formula product (other than follow-on formula) either singly or in combination with one or more of additives 1412, 1413, and 1440; and
  2. soy based follow-on formula either singly or in combination with one or more of additives 1412, 1413, and 1422.

Note 5. Additive 1422 may only be used in soy based follow-on formula, either singly or in combination with one or more of additives 1412, 1413 and 1414.

Note 6. Additive 1440 may only be used in soy based infant formula product (other than follow-on formula), either singly or in combination with one or more of additives 1412, 1413, and 1414.

13.1.1 Special medical purpose product for infants

170

Calcium carbonates

GMP

304

Ascorbyl palmitate

100 mg/L

333

Calcium citrates

GMP

338

Phosphoric acid

450 mg/L

For pH adjustment only

339

Sodium phosphates

450 mg/L

340

Potassium phosphates

450 mg/L

341

Calcium phosphates

450 mg/L

401

Sodium alginate

1 000 mg/L

Only in a product specifically formulated for both the dietary management of metabolic disorders of infants aged 4 months and above and general tube‑feeding of infants aged 4 months and above.

407

Carrageenan

1 000 mg/L

Only in a liquid product that contain hydrolysed proteins and/or amino acids

410

Locust bean (carob bean) gum

5 000 mg/L

Only in a product specifically formulated for reduction of gastro‑oesophageal reflux

412

Guar gum

10 000 mg/L

See Note 1, below.

415

Xanthan gum

1 200 mg/L

Only in a product that is based on hydrolysed protein, amino acids or peptides

440

Pectins

2 000 mg/L

Only in a liquid product that contain hydrolysed protein

5 000 mg/L

Only in a product formulated for infants with gastro-intestinal disorders

471

Mono- and diglycerides of fatty acids

5 000 mg/L

Only in product formulated for diets devoid of proteins

472e

Diacyltartaric and fatty acid esters of glycerol

400 mg/L

1412

Distarch phosphate

25 000 mg/L

See Notes 2 and 7, below.

1413

Phosphated distarch phosphate

25 000 mg/L

See Notes 3 and 7, below.

1414

Acetylated distarch phosphate

25 000 mg/L

See Notes 4 and 7, below.

1422

Acetylated distarch adipate

25 000 mg/L

See Notes 5 and 7, below

1440

Hydroxypropyl starch

25 000 mg/L

Sees Note 6 and 7, below.

1450

Starch sodium octenylsuccinate

20 000 mg/L

See Note 7, below

Note 1. Additive 412 may only be used in a product that contains one or more of the following: hydrolysed proteins; peptides; amino acids.

Note 2. Additive 1412 may only be used in:

  1. a product (other than a product formulated for infants aged 6 to 12 months) either singly or in combination with one or more of additives 1413, 1414 and 1440; and
  2. a product formulated for infants aged 6 to 12 months either singly or in combination with one or more of additives 1413, 1414 and 1422.

Note 3. Additive 1413 may only be used in:

  1. a product (other than a product formulated for infants aged 6 to 12 months) either singly or in combination with one or more of additives 1412, 1414 and 1440; and
  2. a product formulated for infants aged 6 to 12 months either singly or in combination with one or more of additives 1412, 1414 and 1422.

Note 4. Additive 1414 may only be used in:

  1. a product (other than a product formulated for infants aged 6 to 12 months) either singly or in combination with one or more of additives 1412, 1413 and 1440; and
  2. a product formulated for infants aged 6 to 12 months either singly or in combination with one or more of additives 1412, 1413 and 1422.

Note 5. Additive 1422 may only be used in a product formulated for infants aged 6 to 12 months either singly or in combination with one or more of additives 1412, 1413 and 1414.

Note 6. Additive 1440 may only be used in a product (other than a product formulated for infants aged 6 to 12 months) either singly or in combination with one or more of additives 1412, 1413, and 1414.

Note 7. Additives 1412, 1413, 1414, 1422, 1440 and 1450 may only be used in a product that contains hydrolysed proteins, amino acids or both.

\n```\n\n","sortOrder":7},{"sectionNumber":"Sch 19","sectionType":"schedule","heading":"Maximum levels of contaminants and natural toxicants","content":"Schedule 19—Maximum levels of contaminants and natural toxicants\n\n\\[22\\] The table to section S19—4 (Maximum levels of metal contaminants)\n\n| Aluminium | Infant formula, follow-on formula and special medical purpose product for infants (other than special medical purpose product for infants formulated for pre-term infants) | 0.5 |\n| --------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | --- |\n| | Soy-based infant formula products | 1 |\n| | Special medical purpose product for infants formulated for pre-term infants | 0.2 |\n\n\\[23\\] The table to section S19—4 (table item dealing with \"Lead\", entry dealing with the food \"infant formula products\" and its associated maximum level)\n\nRepeal the entry, substitute:\n\n| | Infant formula products | 0.01 |\n| --- | ----------------------- | ---- |\n\n","sortOrder":8},{"sectionNumber":"Sch 25","sectionType":"schedule","heading":"Permitted novel foods","content":"Schedule 25—Permitted novel foods\n\n\\[24\\] Subsection S25—2\n\nRepeal\n\n| Dried marine micro-algae (Schizochytrium sp.) rich in docosahexaenoic acid (DHA) | |\n| --------------------------------------------------------------------------------------------------------- | ---------------------------------------------------------------------------------- |\n| Oil derived from marine micro-algae Schizochytrium sp. (American Type Culture Collection (ATCC) PTA-9695) | 1. May only be added to infant formula products in accordance with Standard 2.9.1. |\n| Oil derived from marine micro-algae (Schizochytrium sp.) rich in docosahexaenoic acid (DHA) | |\n| Oil derived from marine micro-algae (Ulkenia sp.) rich in docosahexaenoic acid (DHA) | |\n\nsubstitute:\n\n| Dried marine micro-algae (Schizochytrium sp.) rich in docosahexaenoic acid (DHA) | 1. May be added to infant formula products in accordance with Standard 2.9.1. |\n| --------------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------- |\n| Oil derived from marine micro-algae Schizochytrium sp. (American Type Culture Collection (ATCC) PTA-9695) | 1. Only permitted for use in infant formula products in accordance with Standard 2.9.1 |\n| Oil derived from marine micro-algae (Schizochytrium sp.) rich in docosahexaenoic acid (DHA) | 1. May be added to infant formula products in accordance with Standard 2.9.1. |\n| Oil derived from marine micro-algae (Ulkenia sp.) rich in docosahexaenoic acid (DHA) | 1. May be added to infant formula products in accordance with Standard 2.9.1. |\n\n\\[25\\] Subsection S25—2 (table item dealing with “Isomalto-oligosaccharide”)\n\nRepeal the table item, substitute:\n\n| Isomalto-oligosaccharide | 1. Must not be added to:food for infants; andformulated supplementary food for young children. |\n| ------------------------ | ---------------------------------------------------------------------------------------------- |\n\n\\[26\\] Subsection S25—2 (table item dealing with “Rapeseed protein isolate”, column headed “Conditions of use”, condition 2)\n\nRepeal the condition, substitute:\n\n| | 2. Must not be added to food for infants. |\n| --- | ----------------------------------------- |\n\n\\[27\\] Subsection S25—2 (table item dealing with “Trehalose”)\n\nRepeal the table item, substitute:\n\n| Trehalose | 1. May be added to infant formula products only as a cryo-preservative for L(+) lactic acid producing microorganisms. |\n| --------- | --------------------------------------------------------------------------------------------------------------------- |","sortOrder":9}],"analysis":{"flash_summary_failed":{"failed":true,"reason":"Unauthenticated. Configure AI_GATEWAY_API_KEY or use a provider module. Learn more: https://ai-sdk.dev/unauthenticated-ai-gateway","source":"analysis-cron"},"flash_summary":{"complexity_score":9,"scope_assessment":{"changed":true,"description":"The instrument redefines core product categories and explicitly creates the 'special medical purpose product for infants' class, narrows/reshapes novel‑food entries for infant formula, and moves many permitted forms/limits into product‑specific tables — effectively changing which foods and ingredients are within the Code’s infant product controls (see Schedule 2 definition changes [4]–[7] and the new novel‑food rules at 1.5.1—3). These adjustments expand and redistribute regulatory coverage across product classes and use‑conditions."},"complexity_factors":["Wide scope of technical amendments across multiple Parts and Standards (Schedules 1 & 2 amend Standards 1.1.1, 1.1.2, 1.3.1, 1.5.1, 2.9.1, 2.9.2, 2.9.3, 2.9.5 and others).","Extensive numerical nutrient tables with minima, maxima and guidance upper levels (see S29—3, S29—4, S29—5, S29—6).","New and revised definitions that change which products are captured (inserting 'special medical purpose product for infants' and replacing definitions of 'infant formula' and 'follow‑on formula' — Schedule 2, items [4]–[7]).","Detailed lists of permitted chemical/forms for vitamins, minerals and electrolytes with product‑class distinctions (S29—23 table).","Conditional and time‑limited permissions (e.g. exclusive use period for bovine lactoferrin — S29—9A; novel food first‑use brand/periods referenced in 1.5.1—3).","Changes to novel‑food sale rules that separate infant formula from other retail foods (new section 1.5.1—3).","Large additive schedule rewrites with product‑specific limits, usage notes and GMP references (Schedule 15, many entries).","Contaminant maximums added/adjusted for infant product classes (S19—4 aluminium and lead entries).","Cross‑references and conditional labelling/packaging rules (inner package definition, nutrition statement format S29—10/S29—10A) increasing compliance and enforcement complexity.","Long transition period where both old and new formulations may be sold for 60 months (cl.4(2)–(3)), creating inventory and supply‑chain management complexity."],"plain_english_summary":"This instrument amends the Australia New Zealand Food Standards Code to change composition, labelling, additive and novel‑food rules for infant formula, follow‑on formula and a new class called special medical purpose products for infants. It sets nutrient minima/maxima, permitted substance forms, additive limits, contaminant limits and a required nutrition‑information format, and creates a 60‑month transition (cl.4). Manufacturers, importers and retailers bear testing, reformulation and relabelling costs; regulators decide permitted forms and conditional uses (see Schedules and definitions changes)."},"kimi_summary":{"_metrics":{"completionTokens":779},"content_quality":"ok","complexity_score":8,"scope_assessment":{"changed":false,"description":"This is a consequential amendments instrument that operates strictly within the scope of Proposal P1028 on infant formula. It makes technical and supporting changes to implement the main proposal without expanding beyond the original policy intent of updating infant formula standards."},"complexity_factors":["Extensive cross-referencing between multiple standards (1.1.2, 1.2.3, 1.3.1, 1.5.1, 2.9.1, 2.9.2, 2.9.3, 2.9.5, S8-2, S15-5, S19-4, S25-2, S29-23)","Numerous detailed tables with precise quantitative requirements (minimums, maximums, guidance upper levels) for 30+ nutrients","Conditional logic for additive use based on product type (powder vs liquid, soy-based vs milk-based, standard vs medical purpose)","Nested exceptions and notes (e.g., additives 1412-1450 with 7 detailed notes restricting use to specific product categories)","Novel food provisions with conditional permissions and exclusive use periods","Transition period mechanics linking commencement to another instrument","Multiple unit conversions required (μg, mg, g, kJ, RE, α-TE, % of fatty acids)","Specific chemical form requirements for nutrients (e.g., 'L-ascorbic acid' not just 'vitamin C')","Brand-specific exclusive use provision for lactoferrin with defined time period"],"plain_english_summary":"This instrument updates the Australia New Zealand Food Standards Code to set detailed nutritional, additive and contaminant rules for infant and follow‑on formulas, and creates a new category for special medical purpose products for infants. It tightens safety limits (including aluminium and lead), permits some new additives, and provides a five‑year transition plus a temporary exclusive use for bovine lactoferrin.\n\nIt primarily affects formula manufacturers and importers, while improving clarity and safety for caregivers and clinicians."}},"importantCases":[],"_links":{"self":"/api/acts/food-standards-proposal-p1028-infant-formula-consequential-amendments-variation","history":"/api/acts/food-standards-proposal-p1028-infant-formula-consequential-amendments-variation/history","analysis":"/api/acts/food-standards-proposal-p1028-infant-formula-consequential-amendments-variation/analysis","conflicts":"/api/acts/food-standards-proposal-p1028-infant-formula-consequential-amendments-variation/conflicts","importantCases":"/api/acts/food-standards-proposal-p1028-infant-formula-consequential-amendments-variation/important-cases","documents":"/api/acts/food-standards-proposal-p1028-infant-formula-consequential-amendments-variation/documents"}}